the course of the disease. Combinations of cyclophosphamide, plasmapheresis, and steroids may also have short-term beneficial effects in MS. Unfortunately immunosuppressive drugs, particularly alkylating agents, have a close therapeutic/toxic ratio and a wide range of side-effects. Although long-term risks of malignant disorders in patients with non-neoplastic disease treated with immunosuppressive drugs are not precisely defined, alkylating agents such as cyclophosphamide have been associated with a higher than expected incidence of malignant disorders of the blood. Even less is known about long-term risks of immunosuppressive drugs in MS. However, in one MS study, a 2.5-fold increased risk of cancer was found in 131 patients treated with azathioprine for a mean of 6 years and malignant disorders occurred in almost 10% of the subgroup of MS patients followed 5 years or longer. TLI seems not to be associated with a high risk of neoplasia and generally produces few serious side-effects in long-term follow-up.

TLI and immunosuppressive drugs in MS each have another theoretical advantage and disadvantage. By sparing the brain, TLI cannot damage its oligodendrogliaocytes, thereby allowing the possibility of remyelination, whereas immunosuppressive drugs which cross a normal or damaged blood-brain barrier might injure the oligodendrogliaocytes and inhibit remyelination. On the other hand, TLI does not eliminate immunocompetent cells in the brain; if MS is an autoimmune disease, these cells could continue to cause immune-mediated tissue injury for their lifetime in the CNS.

TLI therefore appears to be a promising new therapy for the treatment of patients with chronic progressive MS. However, amplification of our results is needed before the overall efficacy of TLI in MS can be judged and the subgroups of patients who might most benefit identified. In the mean time, TLI should be considered an experimental therapy in MS patients and its use in this disorder restricted to MS study groups.

Addendum

Subsequent to completion of this study, 1 severely disabled MS patient, 3 year after TLI, died from a flu-like syndrome complicated by staphylococcal pneumonia, obstruction of her endotracheal tube, and cardiorespiratory arrest.

This work was supported by the Medical Research Service of the Veterans Administration.

Correspondence should be addressed to S. D. C., VA Medical Center, Neurology Service (127), East Orange, New Jersey 07019, USA.

REFERENCES


S. D. COOK AND OTHERS: REFERENCES—continued
Thus, the severity of cirrhosis might affect the density or affinity of beta-adrenoceptors. We have studied beta-adrenoceptor status in patients with cirrhosis of different severity.

**Subjects and Methods**

We compared fifteen cirrhotic patients, ten men and five women, aged 41–76 years (median 56 years), three grade A, nine grade B, three grade C by a modified Child classification, and thirteen controls, seven men and six women, aged 36–81 years (median 55 years). No subject was receiving drugs for treatment of the cardiovascular system. Most of the patients were taking antacids, diuretics (spironolactone 0–400 mg daily, or frusemide 0–80 mg daily), vitamin K, and lactulose. The severity of ascites was determined by physical examination and ultrasound the day before the receptor status determinations. Clinical and laboratory data were collected independently by different physicians and treated separately until statistical analysis.

Mononuclear cells were separated from samples of peripheral blood taken in the morning by means of 'Ficoll-Hyphaque' (Pharmacia, Heidelberg). There is evidence that the beta-2-adrenoceptors on these lymphocytes and monocytes represent those in other organs, and these readily available cells are commonly used for beta-2-adrenoceptor investigations. Specific binding of iodine-125-labelled cyanopindolol (2100 Ci/mmol, Amersham) was measured by incubating 1 ml cell suspension (5 x 10^5 cells) at 37°C for 90 min with or without 0-1 nM timolol. Incubation was ended by centrifugation at 18 000 g. At least eight different ligand concentrations were used for determining the receptor status of each subject. Density of binding sites (B\text{max}) and apparent equilibrium dissociation constant (K\text{d}) as an indicator of affinity were calculated according to Scatchard. Statistical significance was determined by the two-tailed Mann-Whitney test; a p value less than 0.05 was considered significant. Correlations were analysed by polynomial regression.

**Results**

There were no significant differences between the cirrhotic patients and the controls in B\text{max} (509–1958, median 1035, vs 595–2120, median 1034, binding sites per cell) or K\text{d} (1.8–5.3, median 2.7 x 10^{-12} mol/l vs 1.6–8.6, median 4.1 x 10^{-12} mol/l). Neither age nor sex was correlated with B\text{max} or K\text{d} in either group. The heart rate in cirrhotic patients (76–100, median 84 beats/min) was significantly lower than that in controls (60–88, median 68 beats/min). This elevation, possibly indicating increased adrenergic activity of the beta-1-adrenoceptors, was not correlated with the density of beta-2-adrenoceptors. Furthermore, in the cirrhotic patients no correlation was found between beta-receptor status and the dosage of various drugs, particularly the extent of diuretic treatment, or several indicators of the severity of liver disease, such as serum bilirubin, serum albumin, prothrombin time, and Child-Pugh score. There was no significant correlation between B\text{max} and plasma potassium in patient or control group. However, there was a significant (p < 0.01) negative correlation (r = -0.73) between the density of binding sites and the grade of ascites defined by physical examination and ultrasound (fig 1). The reduced receptor density and unchanged affinity in a representative cirrhotic patient with severe ascites are shown in fig 2.

**Discussion**

In view of the high plasma catecholamine levels reported in decompensated cirrhosis, the reduction in beta-2-adrenoceptors in cirrhotic patients with severe ascites can be interpreted as down-regulation. Down-regulation of beta-adrenoceptor density can be assumed to affect the haemodynamic response to beta-blocking drugs. This finding is particularly interesting, since selective beta-2 blockade is being recommended as pharmacological treatment in portal hypertension. Because of the pronounced differences in receptor density between individuals, the determination of beta-adrenoceptor status might prove useful in selecting the appropriate dose of beta-blocking agents. Finally, our findings could offer an explanation for the discrepant results of propranolol treatment for prevention of recurrent gastrointestinal bleeding; patients with severe cirrhosis and severe ascites, included in Burroughs' study, but not in Lebrec's study, may have shown less response to propranolol owing to down-regulation of beta-2-adrenoceptors.

We thank Mrs M. Bauch, Ms S. Kirzinger, Mrs C. Lemmermann, and Ms I. Reitmeier, for technical assistance and Dr G. Geigenberger, Dr W. Krois, Dr A. Mannes, Dr W. Richter, and Dr M. Weinzierl for their cooperation.

**References**

Correspondence should be addressed to A. L. G., Department of Medicine II, Klinikum Grosshadern, Marchioninistrasse 15, D-8000 Munich 70, Federal Republic of Germany.